Genetic variants forecast GLP-1 weight‑loss response and nausea risk
A large GWAS in 23andMe participants identifies a GLP1R missense variant (rs10305420) linked to greater weight loss from GLP‑1 receptor agonists (~0.76 kg per allele) and links GLP1R and GIPR variants to treatment‑related nausea/vomiting, with a tirzepatide‑specific GIPR signal; replication in All of Us EHR data and integrated predictive models show that combining genetic and non‑genetic factors can stratify patients by efficacy and side‑effect risk, advancing precision obesity treatment.
